Our knowledge clearly show that CK18 is consistently expressed in many epithelial cancers, Primarily adenocarcinomas. both equally lack of CK18 expression in cancers derived from CK18 beneficial precursor cells and neo-expression in malignancies derived from CK18 beneficial precursors are typically linked to unfavorable tumor phenotype and disorder